Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology International"
DOI: 10.1007/s12072-018-9861-2
Abstract: IntroductionNew regimens involving direct-acting antiviral agents have recently been approved for the treatment of HCV. Our aim was to assess the efficacy and safety of 12 or 24 weeks of Sofosbuvir 400 mg plus Daclatasvir 60 mg, with… read more here.
Keywords: genotype patients; treatment; receiving weeks; without ribavirin ... See more keywords